Skip to main content
Veterinary Medicines

TENAZYM, Perorální suspenze

Authorised
  • Tetracycline hydrochloride
  • NEOMYCIN SULFATE
  • Prednisolone acetate
  • Trypsin
  • Chymotrypsin
  • Papain

Product identification

Medicine name:
TENAZYM, Perorální suspenze
Active substance:
  • Tetracycline hydrochloride
  • NEOMYCIN SULFATE
  • Prednisolone acetate
  • Trypsin
  • Chymotrypsin
  • Papain
Target species:
  • Cat
  • Dog
Route of administration:
  • Oral use
  • Cutaneous use

Product details

Active substance and strength:
  • Tetracycline hydrochloride
    30.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • NEOMYCIN SULFATE
    22.50
    milligram(s)
    /
    1.00
    millilitre(s)
  • Prednisolone acetate
    2.00
    milligram(s)
    /
    1.00
    millilitre(s)
  • Trypsin
    0.40
    milligram(s)
    /
    1.00
    millilitre(s)
  • Chymotrypsin
    0.40
    milligram(s)
    /
    1.00
    millilitre(s)
  • Papain
    1.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral suspension
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01RV
Authorisation status:
  • Valid
Authorised in:
  • Czechia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Veyx Pharma GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Veyx Pharma GmbH
Responsible authority:
  • Institute For State Control Of Veterinary Biologicals And Medicaments
Authorisation number:
  • 96/045/99-C
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022

Labelling

This document does not exist in this language (English). You can find it in another language below.
Czech (PDF)
Published on: 26/10/2022